Clinical trials
catalyst calendar across sponsors →Studies where LBRX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 1 with posted results
Held by 5 tracked-famous managers (Balyasny Asset Management L.P., MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, TWO SIGMA INVESTMENTS, LP, D. E. Shaw & Co., Inc.) · FINRA short interest 12.8 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| 52-week Open Label Safety-Tolerability StudyNCT07369154Evaluate long term safety and tolerability of LB-102 by evaluating the number of adverse event, incidence of treatment emergent events.Open-label · Treatment | Phase 3 | Recruiting | Drug: LB-102 | Schizophrenia | 900 | Dec 2028 | ≤ 865 d | 2026-07-27 |
| Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.NCT07494305Change From Baseline in Montgomery Åsberg Depression Rating -10 core symptom scale (MADRS-10)Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: LB-102 · Other: Placebo | Bipolar I Disorder | 320 | Feb 2028 | ≤ 559 d | 2026-07-27 |
| Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute SchizophreniaNCT07363577Change from baseline to Week 6 on the Positive and Negative Syndrome ScaleRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: LB-102 (50 mg tablet), LB-102 (100 mg tablet) · Other: Placebo | Schizophrenia | 456 | Jun 2027 | ≤ 315 d | 2026-07-27 |
| Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute SchizophreniaNCT06179108results2025-10-22Change From Baseline to Week 4 in the PANSS Total ScoreRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: LB-102 | Schizophrenia | 359 | 2024-12-04actual | — | 2025-10-22 |
| Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy VolunteersNCT04588129Brain Receptor Occupancy as Measured by Positron Emission TomographyRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: LB-102 | Schizophrenia | 16 | 2021-09-17actual | — | 2022-05-04 |
| Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy AdultsNCT04187560Percentage of participants who experience at least one treatment-emergent adverse event (TEAE)Non-randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: LB-102 | Schizophrenia | 64 | 2020-07-01actual | — | 2020-12-10 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19